Health-Related Quality of Life After Neonatal Treatment of Symptomatic Tetralogy of Fallot: Insights from the Congenital Cardiac Research Collaborative
- PMID: 39305323
- PMCID: PMC12583293
- DOI: 10.1007/s00246-024-03650-2
Health-Related Quality of Life After Neonatal Treatment of Symptomatic Tetralogy of Fallot: Insights from the Congenital Cardiac Research Collaborative
Erratum in
-
Correction: Health-Related Quality of Life After Neonatal Treatment of Symptomatic Tetralogy of Fallot: Insights from the Congenital Cardiac Research Collaborative.Pediatr Cardiol. 2025 Jan;46(1):249-251. doi: 10.1007/s00246-024-03680-w. Pediatr Cardiol. 2025. PMID: 39432099 Free PMC article. No abstract available.
Abstract
To evaluate the association between initial management strategy of neonatal symptomatic Tetralogy of Fallot (sTOF) and later health-related quality of life (HRQOL) outcomes. We performed a multicenter, cross-sectional evaluation of a previously assembled cohort of infants with sTOF who underwent initial intervention at ≤ 30 days of age, between 2005 and 2017. Eligible patients' parents/guardians completed an age-appropriate Pediatric Quality of Life Inventory, a Pediatric Quality of Life Inventory Cardiac Module Heart Disease Symptoms Scale, and a parental survey. The association between treatment strategy and HRQOL was evaluated, and the entire sTOF cohort was compared to published values for the healthy pediatric population and to children with complex congenital heart disease and other chronic illness. The study cohort included 143 sTOF subjects, of which 59 underwent a primary repair, and 84 had a staged repair approach. There was no association between initial management strategy and lower HRQOL. For the entire cohort, in general, individual domain scores decreased as age sequentially increased. Across domain measurements, mean scores for the sTOF cohort were significantly lower than the healthy pediatric population and comparable to those with other forms of complex CHD and other chronic health conditions. The presence of a genetic syndrome was significantly associated with a poor HRQOL (p = 0.003). Initial treatment strategy for sTOF was not associated with differences in late HRQOL outcomes, though the overall HRQOL in this sTOF cohort was significantly lower than the general population, and comparable to others with chronic illness.
Keywords: Congenital heart disease; Quality of life; Tetralogy of fallot.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: While none of the authors have any conflicts of interest related to this study, the following conflicts exist: Dr. Jeffrey Zampi is a Consultant for Medtronic, Inc. and Gore Medical. He also serves on the Data Safety Monitoring Board for Encore Medical. Dr. Athar Qureshi is a Consultant for Medtronic, Inc., Gore Medical, and B. Braun Medical, Inc. Dr. Bryan Goldstein is a Consultant for Medtronic, Inc. and Gore Medical. The authors declare no competing interests.
Figures
References
-
- Loffredo CA (2000) Epidemiology of cardiovascular malformations: prevalence and risk factors. Am J Med Genet 97:319–325 - PubMed
-
- Rumsfeld JS, Alexander KP, Goff DC, Graham MM, Ho PM, Masoudi FA et al (2013) Cardiovascular health: the importance of measuring patient-reported health status: a scientific statement from the American Heart Association. Circulation 127:2233–2249 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
